Safety and efficacy of olmesartan: An observational pooled-analysis of 156,682 hypertensive patients

Expert Opinion on Drug Safety

Volumn 10, Issue 2, 2011, Pages 185-196

  Scholze, Jürgen ^a   Schaefer, Angie ^b   Kreutz, Reinhold ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b DAIICHI SANKYO CO   (Japan)

Author keywords

antihypertensive drugs; efficacy; hypertension; olmesartan; safety; tolerability

Indexed keywords

ANTIHYPERTENSIVE AGENT; HYDROCHLOROTHIAZIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OLMESARTAN;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BREAST DISEASE; COMORBIDITY; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DRY THROAT; DYSGEUSIA; DYSPNEA; EAR DISEASE; ESSENTIAL HYPERTENSION; EYE DISEASE; FEMALE; FORMICATION; GASTROINTESTINAL DISEASE; HEART DISEASE; HEPATOBILIARY DISEASE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; IMMUNOPATHOLOGY; INNER EAR DISEASE; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METABOLIC DISORDER; MONOTHERAPY; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; OBSERVATIONAL STUDY; OROPHARYNX PAIN; PAIN; PARESTHESIA; RASH; RESPIRATORY TRACT DISEASE; SHOCK; SIDE EFFECT; SKIN DISEASE; SYSTOLIC BLOOD PRESSURE; THORAX DISEASE; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; UROGENITAL TRACT DISEASE; URTICARIA; VASCULAR DISEASE; VOMITING;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLES; MALE; MIDDLE AGED; RISK FACTORS; TETRAZOLES; TREATMENT OUTCOME;

EID: 79952319587     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.2011.552426     Document Type: Article

References (35)

1. Guidelines Committee. 2003 European Society of Hypertension- European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53
2. Mancia G, De Backer G, Dominiczak A, et al. 2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press 2007;16:135-232
3. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003;289:2560-72 (Pubitemid 37430158)
4. Erdine S. How well is hypertension controlled in Europe? J Hypertens 2000;18:1348-9
5. Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004;43:10-17
6. Morgan TO, Anderson AI, MacInnis RJ. ACE inhibitors, beta-blockers, calcium blockers, and diuretics for the control of systolic hypertension. Am J Hypertens 2001;14:241-7 (Pubitemid 32202707)
7. Dickerson JE, Hingorani AD, Ashby MJ, et al. Optimisation of antihypertensive treatment bycrossover rotation of four major classes. Lancet 1999;353:2008-13 (Pubitemid 29271745)
8. WHO, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003;21:1983-92
9. Warner GT, Jarvis B. Olmesartan medoxomil. Drugs 2002;62:1345-53 (Pubitemid 34800096)
10. Brunner HR, Laeis P. Clinical efficacy of olmesartan medoxomil. J Hypertens Suppl 2003;21:43-6
11. Chilman-Blair K, Rabesseda X. Olmesartan, an AT1-selective antihypertensive agent. Drugs Today 2003;39:745-61
12. Ball KJ, Williams PA, Stumpe KO. Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives. J Hypertens Suppl 2001;19:49-56
13. Brunner HR. Clinical efficacy and tolerability of olmesartan. Clin Ther 2004;26:28-32
14. Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan and Irbesartan in the control of essential hypertension. J Clin Hypertens 2001;3:283-91
15. Bergmann K, Laeis P, Puchler K, et al. Olmesartan medoxomil influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil. J Hypertens 2001;19:33-40
16. Laeis P, Pucher K, Kirch W. The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. J Hypertens 2001;19:21-32
17. Puchler K, Laeis P, Stumpe K. Blood pressure response, but not adverse event incidence, correlates with dose of Angiotensin II antagonist. J Hypertens 2001;19:41-8
18. Chrysant SG, Weber MA, Wang AC, Hinman DJ. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens 2004;17:252-9 (Pubitemid 38293331)
19. Oparil S, Chrysant SG, Kereiakes D, et al. Results of an olmesartan medoxomil-based treatment regimen in hypertensive patients. J Clin Hypertens 2008;10:911-21
20. Roger VL. Cardiovascular disease surveillance in the comparative effectiveness landscape. Circ Cardiovasc Qual Outcomes 2009;2:404-6
21. National Kidney Foundation. Available from: http://www.kidney.org/ kidneydisease/ckd/knowgfr.cfm#chart [Accessed 18th May 2010]
22. Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Gac Sanit 2007;18:805-35 (Pubitemid 350295185)
23. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59 (Pubitemid 351522739)
24. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003;326(7404):1427
25. White WB. Cardiovascular effects of the cyclooxygenase inhibitors. Hypertension 2007;49:408-18
26. Khosla N, Bakris G. Lessons learned from recent hypertension trials about kidney disease. Clin J Am Soc Nephrol 2006;1:229-35
27. Bakris GL, Sarafidis PA, Weir MR, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010;375:1173-81
28. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press 2009;18:308-47
29. Sellin L, Stegbauer J, Laeis P, Rump LC. Adding hydrochlorothiazide to olmesartan dose dependently improves 24-h blood pressure and response rates in mild-to-moderate hypertension. J Hypertens 2005;23:2083-92 (Pubitemid 41830405)
30. Barrios V, Escobar C, Calderon A, Bohm M. Blood pressure goal achievement with olmesartan medoxomil-based treatment: additional analysis of the OLMEBEST study. Vasc Health Risk Manag 2009;5:723-9
31. Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009;122:290-300
32. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010;55:399-407
33. Brown MJ. Renin: friend or foe? Heart 2007;93:1026-33
34. Destro M, Cagnoni F, D'Ospina A, et al. Role of valsartan, amlodipine and hydrochlorothiazide fixed combination in blood pressure control: an update. Vasc Health Risk Manag 2010;6:253-60
35. Pimenta E, Oparil S. Fixed combinations in the management of hypertension: patient perspectives and rationale for development and utility of the olmesartan-amlodipine combination. Vasc Health Risk Manag 2008;4:653-64 (Pubitemid 352037923)